EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
|
EQS-News: Heidelberg Pharma AG
/ Key word(s): AGM/EGM
PRESS RELEASE Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
Ladenburg, Germany, 23 June 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the company's shareholders approved the management proposals with a large majority (between 98.67% and 98.72%) at today's ordinary virtual Annual General Meeting.
Attendance (incl. postal votes cast) at the 2026 Annual General Meeting corresponded to 80.55% of the current capital stock. For more information on the Annual General Meeting, including the voting results, please visit: https://heidelberg-pharma.com/en/agm. About Heidelberg Pharma Heidelberg Pharma is the first company to develop cancer therapies using Amanitin, a compound derived from the green death cap mushroom. The biological mechanism of action of the toxin represents a new therapeutic modality and is used as a compound in the Amanitin-based ADC technology, the so-called ATAC technology. The lead candidate HDP-101 (INN: pamlectabart tismanitin) is a BCMA ATAC in clinical development for multiple myeloma. The candidate has been granted Orphan Drug Designation and Fast Track Designation from the FDA. A second ATAC candidate, HDP-102 is in clinical development stage in Non-Hodgkin Lymphoma. HDP-103 against metastatic castration-resistant prostate cancer and HDP-104 targeting gastrointestinal tumors such as colorectal cancer have completed preclinical development. These programs are available for partnering. The company is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com ATAC® is a registered trademark of Heidelberg Pharma Research GmbH.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will”, "should”, "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
23.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Gregor-Mendel-Str. 22 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 - 0 |
| Fax: | +49 (0)89 41 31 38 - 99 |
| E-mail: | investors@hdpharma.com |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Munich, Stuttgart, Tradegate BSX |
| EQS News ID: | 2352254 |
| End of News | EQS News Service |
|
|
2352254 23.06.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 8,49 | 1,75 | 18,51 | 9,86 | 6,85 | 1,46 | 0,00 | |
| EBITDA1,2 | -17,55 | -24,83 | -16,62 | -20,33 | -20,64 | -39,28 | 0,00 | |
| EBITDA-Margin3 | -206,71 | -1.418,86 | -89,79 | -206,19 | -301,36 | -2.696,16 | 0,00 | |
| EBIT1,4 | -18,28 | -25,63 | -17,18 | -21,21 | -20,67 | -42,10 | 0,00 | |
| EBIT-Margin5 | -215,31 | -1.464,57 | -92,82 | -215,11 | -301,80 | -2.889,50 | 0,00 | |
| Net Profit (Loss)1 | -18,37 | -26,14 | -19,70 | -20,35 | -19,38 | -42,28 | 0,00 | |
| Net-Margin6 | -216,37 | -1.493,71 | -106,43 | -206,39 | -282,96 | -2.901,92 | 0,00 | |
| Cashflow1,7 | -17,89 | -26,61 | -8,57 | -33,95 | -29,59 | -31,60 | 0,00 | |
| Earnings per share8 | -0,61 | -0,80 | -0,44 | -0,31 | -0,42 | -0,91 | -0,53 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Baker Tilly
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Heidelberg Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A11QVV | DE000A11QVV0 | AG | 123,04 Mio € | 13.11.2006 | Halten | 8FXCFJCP+89 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| -7,74 | 0,00 | 0,00 | -4,78 | -11,27 | -3,89 | 84,45 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 23.06.2026 | 29.04.2026 | 15.07.2026 | 15.10.2026 | 26.03.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -4,40% | -10,45% | +6,05% | -32,74% | -80,94% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
